| Ytd | -1.67% | |
| 1y | 88.40% |
| Open | 30.86 | Prev Close | 31.35 | Low | 30.66 | High | 31.20 | Mkt Cap | 36.50B |
| Vol | 1.54M | Avg Vol | 6.29M | EPS | 2.93 | P/E | 10.70 | Forward P/E | 15.50 |
| Beta | 0.86 | Short Ratio | 5.60 | Inst. Own | 62.40% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 11-27 | Earning | 07-29 | 50-d Avg | 33.73 | 200-d Avg | 30.22 | 1yr Est | 40.90 |
TEVA News
One generates steady cash flow with a lower valuation; the other is growing at 45% but carries highe
Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced
Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net mar
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: a
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE:AN
TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a sub
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to O
Teva secures exclusive global rights to commercialize Polpharma Biologics' biosimilar candidate to O
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE: TEVA) and Samsung Bioepis Co., Ltd. today ann
In a recent interview, legendary investor Bill Ackman was asked about why he was bullish on the econ
Bill Ackman is bullish on Israel. Here's why he thinks investors should watch the region.
Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficac
Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmen
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to advance its TEV-’
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt
Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how e
TEVA is expanding its branded drugs portfolio as Austedo, Ajovy and Uzedy drive higher-margin growth
TEVA files an NDA with the FDA seeking approval of ecopipam for the treatment of pediatric Tourette
The company is seeing higher-margin growth, with EPS rising 72% year over year in the first quarter.
TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TA
TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industr
https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-
Teva has a handful of new biosimilars on the market, with more to come. Those assets will doubtlessl
CHICAGO--(BUSINESS WIRE)--Paragon Biosciences today announced the closing of the sale of Emalex Bios
TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TA
Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcar
PARSIPPANY, N.J. and TEL AVIV, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S
https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men
Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipelin
Wall Street posted modest gains on Wednesday, while gold extended its relentless rally, shattering r
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a
SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares climbed 53.2% to close at $3.14 on Wednes
This Actively Managed ETF Still Has To Earn Its Stripes